fluorouracil has been researched along with Islet Cell Tumor, Malignant in 10 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with carcinoid tumor, a combination of cisplatin (150 mg) and doxorubicin (50 mg) was used." | 2.69 | Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. ( Ajani, JA; Carrasco, CH; Chuang, V; Dumas, P; Kim, YH; Lawrence, D; Richli, W; Wallace, S, 1999) |
| "Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas." | 1.37 | First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. ( Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR, 2011) |
| "Nonfunctioning islet cell tumor of the pancreas is frequently found in young female." | 1.34 | [Management of nonfunctioning islet cell tumors of the pancreas]. ( Ding, XW; Hao, XS; Liang, H; Pan, Y; Wang, BG; Wang, XN, 2007) |
| "Islet cell carcinomas have an incidence of 5 per million per year; 50 per cent of these are nonfunctioning islet cell tumors." | 1.31 | Nonfunctioning islet cell carcinoma of the pancreas: case report. ( Elster, E; Golocovsky, M; Pearl, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshioka, M | 1 |
| Shibata, S | 1 |
| Uchinami, H | 1 |
| Watanabe, G | 1 |
| Miyazawa, H | 1 |
| Iida, M | 1 |
| Yoshida, M | 1 |
| Yoshioka, T | 1 |
| Nanjo, H | 1 |
| Yamamoto, Y | 1 |
| Sugimoto, M | 1 |
| Hines, OJ | 1 |
| Dawson, DW | 1 |
| Muthusamy, VR | 1 |
| Reber, HA | 1 |
| Donahue, TR | 1 |
| Strosberg, JR | 1 |
| Fine, RL | 1 |
| Choi, J | 1 |
| Nasir, A | 1 |
| Coppola, D | 1 |
| Chen, DT | 1 |
| Helm, J | 1 |
| Kvols, L | 1 |
| Pearl, J | 1 |
| Elster, E | 1 |
| Golocovsky, M | 1 |
| Arakawa, Y | 1 |
| Mizunuma, N | 1 |
| Aiba, K | 1 |
| Ito, Y | 1 |
| Takahashi, S | 1 |
| Irie, T | 1 |
| Watanabe, J | 1 |
| Tada, K | 1 |
| Okudaira, T | 1 |
| Seki, M | 1 |
| Yamaguchi, T | 1 |
| Muto, T | 1 |
| Hatake, K | 1 |
| Kouvaraki, MA | 1 |
| Ajani, JA | 3 |
| Hoff, P | 1 |
| Wolff, R | 1 |
| Evans, DB | 1 |
| Lozano, R | 1 |
| Yao, JC | 1 |
| Liang, H | 1 |
| Wang, XN | 1 |
| Wang, BG | 1 |
| Pan, Y | 1 |
| Ding, XW | 1 |
| Hao, XS | 1 |
| Lai, DT | 1 |
| Chu, KM | 1 |
| Thompson, JF | 1 |
| Gallagher, JP | 1 |
| Waugh, R | 1 |
| Storey, DW | 1 |
| Stephen, MS | 1 |
| Rivera, E | 1 |
| Kim, YH | 1 |
| Carrasco, CH | 1 |
| Dumas, P | 1 |
| Richli, W | 1 |
| Lawrence, D | 1 |
| Chuang, V | 1 |
| Wallace, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors[NCT03079440] | Phase 2 | 31 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors[NCT04790708] | 250 participants (Anticipated) | Interventional | 2018-07-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for fluorouracil and Islet Cell Tumor, Malignant
| Article | Year |
|---|---|
Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Doxo | 1998 |
Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma, Islet Cell; | 1999 |
8 other studies available for fluorouracil and Islet Cell Tumor, Malignant
| Article | Year |
|---|---|
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Is | 2015 |
Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Isl | 2017 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
Nonfunctioning islet cell carcinoma of the pancreas: case report.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Islet Cell; Diagnosi | 2002 |
[Pancreatic islet cell carcinoma with multiple hepatic metastases successfully treated with a streptozocin/5-FU regimen--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Drug Administration Schedule; | 2002 |
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Dose-Response Re | 2004 |
[Management of nonfunctioning islet cell tumors of the pancreas].
Topics: Adenoma, Islet Cell; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2007 |
Islet cell carcinoma treated by induction regional chemotherapy and radical total pancreatectomy with liver revascularization and small bowel autotransplantation.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1996 |